Carcinoma  >>  Intuvax (ilixadencel)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuvax (ilixadencel) / Mendus
NCT01525017: A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Completed
1
12
Europe
Combig-DC (allogeneic dendritic cells) Cancer Vaccine
Immunicum AB
Metastatic Renal Cell Carcinoma
12/13
12/13
NCT01974661: Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

Completed
1
18
Europe
COMBIG-DC (ilixadencel), ilixadencel
Immunicum AB, Uppsala University
Hepatocellular Carcinoma
06/17
06/17

Download Options